Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.

[1]  M. Gurney,et al.  3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[2]  K. Stefánsson,et al.  Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. , 2009, ACS chemical biology.

[3]  M. Gurney,et al.  Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[4]  D. Zembower,et al.  Development of a Scalable Process for DG-041, a Potent EP3 Receptor Antagonist, via Tandem Heck Reactions , 2007 .

[5]  J. Vonesch,et al.  Vascular wall–produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors , 2007, The Journal of experimental medicine.

[6]  C. Li,et al.  Comparison between two classes of selective EP3 antagonists and their biological activities , 2006 .

[7]  D. Denis,et al.  Structure–activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP3 antagonists , 2005 .

[8]  D. Denis,et al.  Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor. , 2003, Bioorganic & medicinal chemistry letters.

[9]  D. Denis,et al.  Structure–Activity Relationship of Biaryl Acylsulfonamide Analogues on the Human EP3 Prostanoid Receptor , 2002 .

[10]  S. Narumiya,et al.  Increased Bleeding Tendency and Decreased Susceptibility to Thromboembolism in Mice Lacking the Prostaglandin E Receptor Subtype EP3 , 2001, Circulation.

[11]  D. Denis,et al.  Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. , 2001, Bioorganic & medicinal chemistry.

[12]  S. Narumiya,et al.  Characterization of EP receptor subtypes responsible for prostaglandin E2‐induced pain responses by use of EP1 and EP3 receptor knockout mice , 2001, British journal of pharmacology.

[13]  D. Denis,et al.  Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry. , 2001, Bioorganic & medicinal chemistry letters.

[14]  Atsushi Ichikawa,et al.  Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3 , 1998, Nature.

[15]  W. Mendelson,et al.  The Regioselective 4-Benzylation of 2,4-Dihydroxybenzaldehyde , 1996 .

[16]  S. Narumiya,et al.  International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. , 1994, Pharmacological reviews.

[17]  G. Baxter,et al.  In vitro characterization of prostanoid EP‐receptors in the non‐pregnant human myometrium , 1991, British journal of pharmacology.

[18]  P. G. Gassman,et al.  The low-temperature, ionic Diels-Alder addition of vinyl ortho esters to 1,3-dienes , 1988 .

[19]  M. -. Chen,et al.  Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase. , 1988, Gastroenterology.

[20]  M. P. Yeh,et al.  Synthesis and reactivity toward acyl chlorides and enones of the new highly functionalized copper reagents RCu(CN)ZnI , 1988 .

[21]  M. Krohn,et al.  3,4-Disubstituted indole acylsulfonamides: a novel series of potent and selective human EP3 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[22]  M. Sisido,et al.  Synthesis and DNA Binding Property of a Novel Peptide Nucleic Acid that Contains cis-4-Adeninyl-L-prolinol Unit , 2001 .